Zora Biosciences is a Finnish diagnostics discovery company. The company identifies robust markers of heart disease and develops them into high-throughput, health-economic value-added clinical methods.
In June 2016 the company announced the signing of an agreement with US origin Mayo Medical Laboratories to collaborate on Plasma Ceramide Testing. The test results may help the patients with coronary artery disease.

Eversheds has assisted and advised the client, Zora Biosciences Ltd., in all legal issues since the establishment of the company.